Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
₩ 18360
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Onconic Therapeutics, Inc. is a biopharmaceutical company. It engages in the research and development of new drugs in the field of acid-related diseases and anti cancer. The company was founded on May 7, 2020 and is headquartered in Seoul, South Korea.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITD.
Data is available to registered users only